Drug profile · INN
varenicline
PHARMACOR VARENICLINE
varenicline (PHARMACOR VARENICLINE) is a neuronal acetylcholine receptor; alpha4/beta2 partial agonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — varenicline
- US status
- approved
- Class
- Nervous system (N07)
- Route
- ORAL
- Patents
- 2
- Programs
- 21
- Data quality
- 0.89
Quick answer
varenicline (PHARMACOR VARENICLINE) is a neuronal acetylcholine receptor; alpha4/beta2 partial agonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
Primary target: Neuronal acetylcholine receptor; alpha4/beta2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is varenicline?
varenicline (PHARMACOR VARENICLINE) is a neuronal acetylcholine receptor; alpha4/beta2 partial agonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for varenicline?
PHARMACOR VARENICLINE is a marketed brand name for varenicline. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of varenicline?
varenicline has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.